MethylGene Inc.

Presenter: Donald Corcoran, President & CEO

Company Profile

MethylGene Inc. (TSX: MYG) is a publicly-traded, clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics with a focus on cancer. The Company's product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases that is in Phase I and Phase II clinical trials for cancer; MGCD290, a fungal Hos2 inhibitor being developed for use in combination with fluconazole for serious fungal infections that is in Phase I clinical studies which are nearing completion; and mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor for cancer which has been in multiple Phase II clinical trials and is licensed to Taiho Pharmaceutical Co. Ltd in certain Asian countries. A fourth compound discovered using MethylGene's HDAC platform, EVP-0334 - a potential cognition enhancing agent, is in Phase I trials sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company's proprietary kinase inhibitor chemistry.

Programs

MGCD265: a multi-targeted kinase (Met) inhibitor for cancer; MGCD290: a Hos2 fungal inhibitor; and mocetinostat: a histone deacetylase inhibitor

Management Team

Donald Corcoran, President and CEO; Jeffrey Besterman, Exec VP of R&D and CSO; Klaus Kepper, VP Finance and CFO; Charles Grubsztajn, VP Business Development

Presenter Bio

Mr. Corcoran has been MethylGene's President and Chief Executive Officer since the Company's inception in 1997. Mr. Corcoran has over 25 years of experience in the biotechnology, pharmaceutical and health care industries. His background includes responsibilities in the areas of finance, accounting, marketing, human resources, business development and acquisitions/strategic planning. He was instrumental in the creation of MethylGene Inc. during his tenure as Vice President, Business Development at Hybridon, Inc., a publicly-traded drug research and development company based in Cambridge, Massachusetts. During his time at Hybridon, Inc., Mr. Corcoran was responsible for establishing a number of corporate alliances with multinational health care companies. Prior to that time, he served as Business Planning Manager at Schering-Plough Corporation and served in a variety of managerial and staff positions at Eli Lilly and Company from 1982 to 1991. Mr. Corcoran is a director of Tranzyme Inc., a private United States development stage biotechnology company located in Research Triangle Park, North Carolina. Mr. Corcoran received a B.A. in Economics and Biology from Union College, New York and an MBA from Cornell University's Johnson Graduate School of Management.

Contact

MethylGene Inc.
7220 Frederick Banting
Montreal
Quebec, Canada
H4S 2A1

ph: 514-337-3333
fx: 514-337-0550

ww.methylgene.com
corcorand@methylgene.com